Transvenous or subcutaneous implantable cardioverter defibrillator: a review to aid decision-making.
Transvenous or subcutaneous implantable cardioverter defibrillator: a review to aid decision-making.
The implantable cardioverter-defibrillator (ICD) is a proven treatment for preventing sudden cardiac death. Transvenous leads are associated with significant mortality and morbidity, and the subcutaneous ICD (S-ICD) addresses this. However, it is not without limitations, in particular the absence of anti-tachycardia pacing. The decision of which device is most suitable for an individual patient is often complex. Here, we review the relative merits and weaknesses of both the transvenous and S-ICD. We summarise the available evidence for each device in particular patient cohorts, namely: ischaemic and non-ischaemic cardiomyopathy, idiopathic ventricular fibrillation, Brugada syndrome, long QT syndrome, arrhythmogenic right ventricular cardiomyopathy, and hypertrophic cardiomyopathy.
545-555
Leo, Mileno
a9342a4e-2bd1-4c2a-bc1b-46a8ffa29842
Sharp, Alexander J.
1b75e163-d071-48d8-ad86-0c5ce163a0f4
Briosa e Gala, Andre
409c30a8-0696-4426-9f9b-2539af465dbd
Pope, Michael T.B.
2ead06ce-b133-4455-a0d1-7bb899e437de
Betts, Timothy R.
a9d90073-a54a-478c-81f0-39ecc5234047
14 July 2022
Leo, Mileno
a9342a4e-2bd1-4c2a-bc1b-46a8ffa29842
Sharp, Alexander J.
1b75e163-d071-48d8-ad86-0c5ce163a0f4
Briosa e Gala, Andre
409c30a8-0696-4426-9f9b-2539af465dbd
Pope, Michael T.B.
2ead06ce-b133-4455-a0d1-7bb899e437de
Betts, Timothy R.
a9d90073-a54a-478c-81f0-39ecc5234047
Leo, Mileno, Sharp, Alexander J., Briosa e Gala, Andre, Pope, Michael T.B. and Betts, Timothy R.
(2022)
Transvenous or subcutaneous implantable cardioverter defibrillator: a review to aid decision-making.
Journal of Interventional Cardiac Electrophysiology, 68, .
(doi:10.1007/s10840-022-01299-6).
Abstract
The implantable cardioverter-defibrillator (ICD) is a proven treatment for preventing sudden cardiac death. Transvenous leads are associated with significant mortality and morbidity, and the subcutaneous ICD (S-ICD) addresses this. However, it is not without limitations, in particular the absence of anti-tachycardia pacing. The decision of which device is most suitable for an individual patient is often complex. Here, we review the relative merits and weaknesses of both the transvenous and S-ICD. We summarise the available evidence for each device in particular patient cohorts, namely: ischaemic and non-ischaemic cardiomyopathy, idiopathic ventricular fibrillation, Brugada syndrome, long QT syndrome, arrhythmogenic right ventricular cardiomyopathy, and hypertrophic cardiomyopathy.
This record has no associated files available for download.
More information
Accepted/In Press date: 6 July 2022
Published date: 14 July 2022
Identifiers
Local EPrints ID: 504486
URI: http://eprints.soton.ac.uk/id/eprint/504486
PURE UUID: f79a345c-4628-4cbf-b6dc-9351adfd2348
Catalogue record
Date deposited: 10 Sep 2025 15:17
Last modified: 11 Sep 2025 03:22
Export record
Altmetrics
Contributors
Author:
Mileno Leo
Author:
Alexander J. Sharp
Author:
Andre Briosa e Gala
Author:
Michael T.B. Pope
Author:
Timothy R. Betts
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics